source
- Chiesi signs $1.9B deal to acquire KalVista and its approved drugChiesi is buying commercial biotech KalVista Pharmaceuticals for about $1.9 billion in an extension of the industry's vigorous spring shopping spree. The Italian pharma will pay $27 per share {$KAL…Endpoints · 3mo ago↗ source
- Should pharma be swinging bigger with AI? One top researcher wants to tryRIO DE JANEIRO — Kyunghyun Cho says he's a free man once again. He makes that observation, semi-jokingly, while looking over countless rows of poster presentations on the sidelines of the Internati…Endpoints · 3mo ago↗ source
- GSK CEO says team reorg could be in the cards pending upcoming Phase 3 readoutsGSK is expecting several key late-stage readouts this year and, if they do not succeed, the company could change its team structure, CEO Luke Miels said during its first-quarter earnings call with…